Home Medizin Metrion Biosciences verstärkt sein Team mit drei wichtigen Ernennungen

Metrion Biosciences verstärkt sein Team mit drei wichtigen Ernennungen

von NFI Redaktion

Metrion Biosciences Limited („Metrion“), a contract research organization (CRO) and drug discovery company specializing in ion channels, has promoted Clare Rutty to CFO and welcomed two new team members: Sue Peffer as Marketing Director and Leanne Clarke as HR Director. These appointments align with the company’s recent equity financing announcement, strengthening the leadership team to support continued growth.

Clare Rutty, who has been instrumental in the financial growth of Metrion, has been promoted to Chief Financial Officer (CFO). Since joining Metrion, Clare has helped drive the company’s revenue from £1.5 million in the fiscal year ending December 31, 2018, to £5.3 million in 2022, with further growth projected for 2023.

With a 55% increase in the Metrion team to 42 employees since 2022, the company has expanded its services and revenue streams. Clare played a key role in securing a new equity financing round of £2.7 million in 2021 led by Gresham House Ventures and, more recently, a £3.7 million equity financing round led by Maven Capital Partners in December 2023.

In her new role as Marketing Director, Sue Peffer will oversee all marketing activities. Sue brings marketing experience in the life sciences sector from companies like Cresset, Capsugel (now Lonza), and The Automation Partnership (now Sartorius Stedim Biotech), increasing the gender diversity within Metrion’s leadership team.

As a service-focused company, the employees at Metrion are its most valuable asset. In her role as HR Director, Leanne Clarke will ensure Metrion attracts top talent and maintains a workplace where everyone can reach their full potential.

“Ensuring that Metrion appoints high-caliber employees is crucial to our success. We are proud that women currently make up 42% of the Metrion team—a significantly higher percentage than the average of 39% for women working in research and development in drug discovery in the UK. These new appointments and Clare’s promotion reflect the growth and increasing maturity of our company and are in line with our goal of equal representation within our workforce.”

Dr. Andrew Southan, CEO, Metrion Biosciences

“I am delighted to join the Board at the close of the 2023 financing round and look forward to working with the directors and the broader Metrion team as the company continues to evolve.”

Clare Rutty, CFO, Metrion Biosciences

“I am excited to join Metrion at this exciting time for the company. Doing so at a time when other colleagues are being promoted and welcomed makes me proud to be part of an organization that recognizes female talent.”

Sue Peffer, Marketing Director, Metrion Biosciences

“I am thrilled to join Metrion and contribute to its continued growth and success in an extremely challenging market. I look forward to working with the talented team and creating a supportive environment where employees can thrive and contribute to advancements in the field of biosciences.”

Leanne Clarke, HR Director, Metrion Biosciences

For more information, visit: https://www.metrionbiosciences.com/.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.